Given the significance of p-Tau as a risk factor for neurodegenerative diseases, particularly Alzheimer’s disease, we conducted further evaluations of Tau protein levels using immunohistochemistry (IHC). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.